Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic#Savara #Presented #Data #Pivotal #Phase #IMPALA2 #Trial #Molgramostim #Inhalation #Solution #Molgramostim #Patients #Autoimmune #Pulmonary #Alveolar #Proteinosis #aPAP #American #Thoracic